Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Virology

• Publication date

  2017-11-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.01588-17PMID 29167344PMCID PMC5790931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus.

  2018cited by this paper
• Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017

  2017cited by this paper
• Characteristics of the emerging chicken-origin highly pathogenic H7N9 viruses: A new threat to public health and poultry industry.

  2017cited by this paper
• Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models

  2017cited by this paper
• Role of Neuraminidase in Influenza A(H7N9) Virus Receptor Binding

  2017cited by this paper
• Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic — China, October 2016–February 2017

  2017cited by this paper
• Assessing Change in Avian Influenza A(H7N9) Virus Infections During the Fourth Epidemic - China, September 2015-August 2016.

  2016cited by this paper
• Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

  2016cited by this paper
• H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets.

  2016cited by this paper
• Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

  2016cited by this paper
• Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses

  2016cited by this paper
• Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

  2016cited by this paper
• Identification of amino acids in H9N2 influenza virus neuraminidase that are critical for the binding of two mouse monoclonal antibodies.

  2016cited by this paper
• An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.

  2016influential reference
• Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

  2015cited by this paper
• Immunogenicity and Protective Efficacy of a Vero Cell Culture-Derived Whole-Virus H7N9 Vaccine in Mice and Guinea Pigs

  2015cited by this paper
• H7N9: preparing for the unexpected in influenza.

  2015cited by this paper
• Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.

  2015cited by this paper
• Influenza neuraminidase as a vaccine antigen.

  2015cited by this paper
• Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers

  2015cited by this paper
• Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

  2015cited by this paper
• Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice

  2015cited by this paper
• Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses

  2015cited by this paper
• An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.

  2014cited by this paper
• Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

  2014cited by this paper
• Influenza A H1N1 Pandemic Strain Evolution – Divergence and the Potential for Antigenic Drift Variants

  2014cited by this paper
• Single-Domain Antibodies Targeting Neuraminidase Protect against an H5N1 Influenza Virus Challenge

  2014cited by this paper
• Human infection with a novel avian-origin influenza A (H7N9) virus.

  2013cited by this paper
• Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

  2013cited by this paper
• Universal anti-neuraminidase antibody inhibiting all influenza A subtypes.

  2013cited by this paper
• Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase

  2013cited by this paper
• Molecular Basis for Broad Neuraminidase Immunity: Conserved Epitopes in Seasonal and Pandemic H1N1 as Well as H5N1 Influenza Viruses

  2013cited by this paper
• A Contributing Role for Anti-Neuraminidase Antibodies on Immunity to Pandemic H1N1 2009 Influenza A Virus

  2011cited by this paper
• Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses

  2011cited by this paper
• MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

  2011cited by this paper
• A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.

  2010cited by this paper
• Influenza neuraminidase as a vaccine antigen.

  2009cited by this paper
• Influenza Virus Neuraminidase: Structure and Function

  2009cited by this paper
• Amino Acid 226 in the Hemagglutinin of H9N2 Influenza Viruses Determines Cell Tropism and Replication in Human Airway Epithelial Cells

  2007cited by this paper
• Generation of influenza A viruses entirely from cloned cDNAs.

  1999cited by this paper
• N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free energy calculations capture specificity trends observed with mutant binding data.

  1994cited by this paper
• Influenza virus neuraminidase: Structure, antibodies, and inhibitors

  1994cited by this paper
• Transfer of the hemagglutinin activity of influenza virus neuraminidase subtype N9 into an N2 neuraminidase background.

  1991cited by this paper
• Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.

  1990cited by this paper
• Three-dimensional structures of influenza virus neuraminidase-antibody complexes.

  1989cited by this paper
• Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies.

  1987cited by this paper
• Three-dimensional structure of a complex of antibody with influenza virus neuraminidase

  1987cited by this paper
• Antigenic structure and variation in an influenza virus N9 neuraminidase

  1987influential reference
• Influenza virus neuraminidase with hemagglutinin activity.

  1984cited by this paper
• Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

  1979cited by this paper
• Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion

  1976cited by this paper
• Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

  1974cited by this paper
• Effect of neuraminidase antibody on Hong Kong influenza.

  1973cited by this paper
• Association of serum anti-neuraminidase antibody with resistance to influenza in man.

  1972cited by this paper

• Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase.

  2026cites this paper
• Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.

  2025cites this paper
• Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.

  2025cites this paper
• A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice

  2024cites this paper
• The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017

  2024cites this paper
• Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years

  2022cites this paper
• Monoclonal antibodies targeting the influenza virus N6 neuraminidase

  2021cites this paper
• Identification of key residues involved in the neuraminidase antigenic variation of H9N2 influenza virus

  2021cites this paper
• Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic

  2021cites this paper
• Evolution and Antigenic Advancement of N2 Neuraminidase of Swine Influenza A Viruses Circulating in the United States following Two Separate Introductions from Human Seasonal Viruses

  2021cites this paper
• Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

  2021cites this paper
• Antigenic characterization of influenza and SARS-CoV-2 viruses

  2021cites this paper
• Aerosol Transmission from Infected Swine to Ferrets of an H3N2 Virus Collected from an Agricultural Fair and Associated with Human Variant Infections

  2020cites this paper
• Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection

  2020cites this paper
• Antivirals Targeting the Neuraminidase.

  2020cites this paper
• Sialidase activity in human pathologies

  2019cites this paper
• Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.

  2019cites this paper
• The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain

  2019cites this paper
• Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.

  2019influential citation
• The complex crystal structure of neuraminidase from A/Minnesota/11/2010 with B10 antibody.

  2019cites this paper
• Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.

  2018cites this paper
• Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.

  2018cites this paper
• The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice

  2018cites this paper